Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supplyAnaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) and AnaptysBio, Inc. (An ...

Company Summary - AnaptysBio, Inc. (ANAB) is currently positioned as an intriguing investment choice due to solid earnings estimate revisions and a favorable Zacks Rank of 2 (Buy) [1][4]. - Over the past month, the current quarter earnings estimates have improved from a loss of $1.63 per share to a loss of $1.61 per share, while the current year estimates have narrowed from a loss of $6.10 per share to a loss of $6.08 per share [4]. Industry Summary - The Medical - Biomedical and Genetics industry is experiencing positive trends, reflected in its Zacks Industry Rank of 63 out of more than 250 industries, indicating a strong position compared to other segments [2]. - The overall strength of the industry suggests that rising trends may benefit multiple securities within this sector, making it an attractive area for investment [2][5].

Company Presentation - AnaptysBio Inc's president and CEO Daniel Faga will present at the 43rd Annual J P Morgan Healthcare Conference on January 14 2025 at 4 30pm PT 7 30pm ET [1] - A live webcast of the presentation will be available on the investor section of the Anaptys website with a replay available for at least 30 days following the event [2] Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [3] - The company's lead program rosnilimab is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis [3] - AnaptysBio's portfolio includes ANB033 in Phase 1 trials and ANB101 soon to enter clinical development [3] - The company has licensed multiple therapeutic antibodies to GSK including an anti-PD-1 antagonist and an anti-TIM-3 antagonist [3] Contact Information - Nick Montemarano Senior Director of Investor Relations and Strategic Communications can be reached at 858 732 0178 or investors@anaptysbio com [4]

Core Viewpoint - AnaptysBio, Inc. (ANAB) experienced a significant decline in share price by 32.8% following the announcement of unsuccessful results from its phase IIb study of ANB032, a BTLA agonist, leading to the discontinuation of further investment in this asset [1][2][9]. Company Performance - AnaptysBio's stock has decreased by 27.6% year-to-date, contrasting with an industry decline of 8.1% [3]. Study Details - The ARISE-AD study assessed the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 in patients with moderate-to-severe atopic dermatitis, enrolling 201 patients with a mean baseline EASI score of 27.3 [4][5]. - Patients were randomized to receive different dosages of ANB032 or placebo over 12 weeks, but the drug did not meet the primary endpoint of achieving at least a 75% improvement in EASI score [6]. - None of the secondary endpoints were met, including EASI-90 and itch severity reduction, with higher placebo response rates observed particularly in the U.S. [7]. Safety Profile - Despite the disappointing efficacy results, ANB032 was well tolerated across all doses, with no safety signals reported [8]. Future Focus - AnaptysBio plans to shift focus to other candidates, including rosnilimab for rheumatoid arthritis and ANB033 and ANB101 in clinical development [10][11]. - The company anticipates a cash balance of approximately $415 million by the end of 2024, extending its cash runway guidance through the end of 2027 [12].

Core Insights - AnaptysBio, Inc. announced that investigational ANB032 did not meet primary and secondary endpoints in the ARISE-AD trial for moderate-to-severe atopic dermatitis [1][4] - The company will discontinue further investment in ANB032 and focus on its autoimmune portfolio [2] - ANB032 was well tolerated with no safety signals observed across all doses [6] Study Details - The ARISE-AD trial enrolled 201 patients with a mean baseline EASI score of 27.3, including both biologics naïve and experienced patients [2] - Patients were randomized to receive different dosing regimens of ANB032 or placebo for 12 weeks [3] - The primary endpoint was not met, with no significant improvement in EASI-75 or other secondary endpoints at Week 14 [4] Efficacy Observations - Absolute response rates approached the minimum target product profile, but higher placebo response rates were noted, particularly in the U.S. [5] - Despite the lack of efficacy, ANB032 was reported to be safe and well tolerated [6] Market Reaction - Following the announcement, AnaptysBio's stock price fell by 36.3%, trading at $14.72 [7]

Core Insights - AnaptysBio, Inc. announced that its investigational drug ANB032 did not meet primary and secondary endpoints in the ARISE-AD trial for moderate-to-severe atopic dermatitis, leading to the decision to discontinue further investment in this asset [1][2][3] - The company plans to focus resources on its autoimmune portfolio, particularly on rosnilimab, which targets PD-1+ T cells, with upcoming data releases anticipated in early 2025 and 2026 [2][7] - AnaptysBio reported a year-end 2024 cash balance of approximately $415 million, extending its cash runway guidance through the end of 2027, excluding potential milestones and royalties from GSK [1][2] Study Details - The ARISE-AD study involved 201 patients with a mean baseline EASI score of 27.3, randomized to receive different doses of ANB032 or placebo over 12 weeks [2][3] - ANB032 was well tolerated across all doses, with no safety signals observed, although it did not achieve the primary endpoint of EASI-75 improvement [3][5] - The study noted higher placebo response rates than historical norms, particularly in the U.S., despite some durable off-drug responses observed in patients treated with ANB032 [4][5] Future Developments - AnaptysBio anticipates sharing top-line Phase 2b data for rosnilimab in rheumatoid arthritis in February 2025, followed by Phase 2 data for ulcerative colitis in Q1 2026 [2][7] - The company is also advancing other programs, including ANB033 and ANB101, with ANB033 currently in Phase 1 trials [7]

Company Overview - AnaptysBio, Inc. (ANAB) is part of the Medical group, which consists of 1022 companies and ranks 3 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Analysis - Year-to-date, AnaptysBio, Inc. has returned approximately 4%, outperforming the Medical sector's average return of 0.5% [4] - Over the past three months, the Zacks Consensus Estimate for ANAB's full-year earnings has increased by 11.9%, reflecting improved analyst sentiment [4] Industry Context - AnaptysBio, Inc. operates within the Medical - Biomedical and Genetics industry, which includes 504 stocks and currently ranks 65 in the Zacks Industry Rank [6] - Stocks in this industry have experienced an average loss of about 7% year-to-date, indicating that ANAB is performing better than its peers in this specific sector [6] Comparative Analysis - Another notable stock in the Medical sector, Castle Biosciences, Inc. (CSTL), has achieved a year-to-date return of 38.1% and has a Zacks Rank of 1 (Strong Buy) [5] - Both AnaptysBio, Inc. and Castle Biosciences, Inc. are expected to continue their solid performance in the Medical sector [7]

Core Viewpoint - AnaptysBio, Inc. (ANAB) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to stock price fluctuations based on their buying or selling activities [4]. Business Outlook - The upgrade in Zacks Rank for AnaptysBio indicates an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10]. - Over the past three months, the Zacks Consensus Estimate for AnaptysBio has increased by 3.4%, reflecting analysts' growing confidence in the company's earnings potential [8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - AnaptysBio's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - AnaptysBio, Inc. (ANAB) has experienced significant selling pressure, resulting in a 32.8% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) for ANAB is currently at 28.5, indicating that the stock may be oversold and could be poised for a rebound as selling pressure exhausts [5] - The RSI is a momentum oscillator that ranges from 0 to 100, with a reading below 30 typically signaling that a stock is oversold [2][3] Group 2: Earnings Estimates - There has been a 6.1% increase in the consensus EPS estimate for ANAB over the last 30 days, driven by a strong agreement among sell-side analysts to raise earnings estimates for the current year [5] - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [5] Group 3: Zacks Rank - ANAB holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, suggesting a potential turnaround for the stock [6]

Core Insights - AnaptysBio, Inc. reported a quarterly loss of $1.14 per share, which was better than the Zacks Consensus Estimate of a loss of $1.72, representing an earnings surprise of 33.72% [1] - The company achieved revenues of $30.02 million for the quarter ended September 2024, significantly surpassing the Zacks Consensus Estimate by 279.19%, compared to revenues of $3.32 million a year ago [2] - AnaptysBio shares have underperformed the market, losing about 6.9% since the beginning of the year, while the S&P 500 gained 19.8% [3] Financial Performance - Over the last four quarters, AnaptysBio has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$1.74 on revenues of $8.11 million, and for the current fiscal year, it is -$6.84 on revenues of $31.89 million [7] Industry Context - AnaptysBio operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 38% of over 250 Zacks industries [8] - The industry’s performance can significantly impact AnaptysBio's stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of AnaptysBio's stock price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for AnaptysBio is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]